CLAIMS

1. A pharmaceutical composition suitable for oral administration, in the form of semisolid matrix, comprising:
an active ingredient poorly soluble in water and present in a quantity of from 15 to 45% by weight of the percent composition of the pharmaceutical composition; a surfactant agent constituted by a polyglycolised glyceride; and a pharmaceutically acceptable hydrophilic carrier.

2. A composition according to claim 1, wherein the active ingredient is present in a quantity of from 20 to 40% by weight of the percent composition of the pharmaceutical composition.

3. A composition according to claims 1 or 2, wherein the active ingredient is constituted by an indolinone derivative represented by the general formula (I)



(I)

wherein A is a pyrrolic ring, optionally substituted in one or more positions with equal or different groups, selected among linear or branched lower alkyl, alkoxy, aryl, aryloxy, alkylaryl, alkoxyaryl, or groups $-(CH_2)_mCO_2H$ or -CONHR', where m is 0 or an integer between 1 and 3 and R' is a linear or branched lower alkyl, optionally substituted with one or more equal or different groups, selected among hydroxy, heterocyclyl, amine, alkylamine, dialkylamine; the indolinonic ring being optionally further substituted in one or more of the positions 4, 5, 6 and 7 with equal or

different groups, selected among linear or branched lower alkyl, alkoxy, aryl, alkylaryl or alkoxyaryl.

5. A pharmaceutical composition according to claim 3, wherein the indolinone derivative is selected from the group consisting of SU 5416, SU 6668, SU 10944, SU 10994, SU 14813, SU 11248 and the respective pharmaceutically acceptable salt forms.

6. A composition according to any one of claims 1 to 4, wherein the surfactant agent is selected from the group consisting of Labrasol®, Labrafil® M2125 and Labrafil® M1944.

7. A composition according to any one of claims 1 to 5, wherein the carrier is a saturated polyglycolised glyceride or a polymer with low melting point.

8. A composition according to claim 6 wherein the carrier is selected between Gelucire® 44/14 and Lutrol® F68.

9. A composition according to any one of claims 1 to 7, comprising SU-6668, Labrasol® and Gelucire® 44/14.

10. A composition according to any one of claims 1 to 7, comprising SU-14813, Labrasol® and Gelucire® 44/14

11. A composition according to any one of claims 1 to 7, comprising SU-14813, Lutrol® F68 and Labrasol®.

12. A composition according to any one of claims 1 to 10 further comprising an agent that favours dispersion and/or a surfactant and/or an agent that modifies viscosity and/or antioxidant and chelating agents and/or solubilising agents.

13. An oral formulation comprising a capsule and, as its content, the pharmaceutical composition in semi-solid form as defined in any one of claims 1 to 11.

14. An oral formulation according to claim 12 for use in the treatment cancer.

15. Use of an indolinone derivative according to claim 3, a surfactant agent consisting of a polyglycolised glyceride and a pharmaceutically acceptable hydrophilic carrier, in the preparation of a medicament intended for oral administration in the treatment of cancer.

16. Use of Labrasol®, Labrafil® M2125 or Labrafil® M1944 as surfactant agents in a pharmaceutical composition comprising an indolinone derivative according to claim 3 and a pharmaceutically acceptable hydrophilic carrier.

17. Use of Labrasol® as surfactant agent in a pharmaceutical composition comprising an indolinone derivative according to claim 3 and Gelucire® 44/14.

18. Use of Labrasol® as surfactant agent in a pharmaceutical composition comprising SU 6668 and Gelucire® 44/14.

19. A method for preparing the pharmaceutical composition according to claim 3, comprising: dissolving or dispersing the indolinone derivative in the surfactant agent, until obtaining a homogeneous and viscous mixture; and adding under stirring the mixture thus obtained to the molten carrier until obtaining a homogeneous mixture.